Hot Topics from Texas Pharmacy Association January 2023

From Texas Pharmacy Association:

To help our local affiliates share what’s going on with TPA at their monthly meetings and to foster stronger connections with TPA, the attached PowerPoint presentation is available for use at your meetings this month. You’re welcome to use this however you wish, such as presenting it on screen or having someone read highlights to the group. Knowing that you may still not be meeting in person, we’ve also attached a PDF file that you may wish to forward to your members instead.

This is NOT meant to be an exhaustive review of everything happening at TPA, just a high-level overview summarizing some recent activities, upcoming events, and encouraging involvement/member benefits. We are happy to hear that many of you find this helpful. As always, we welcome your feedback.

Download the PDF file .

DAPA Mentorship Program

Student/Pharmacist Mentorship Program

Mark your calendars!
We’re SUPER excited to launch our new Student/Pharmacist Mentorship Program and we’re SUPER excited to have you join us either as a Mentor or Mentee!
As a part of our DAPA membership engagement initiatives, we’re starting a student-pharmacist mentorship program as requested by our members.
The goal of this mentorship program is to connect our pharmacy students with pharmacists in their interested fields so the students can have a better insight in to their future career choices.
This will increase our DAPA membership engagement and have our pharmacy students to continue being DAPA/TPA members after graduation!
With much feedback, we saw the need and desire for local pharmacists to mentor pharmacy students as they navigate through the career-world of pharmacy. Our student liaisons, Mahsa Helforoush and Alan Linh Nguyen of Texas Tech University of Health Sciences Center, and Elizabeth Beard, PharmD, Co-Chair of the Social Events and Outreach Committee have volunteered and committed their time to make this event possible.
We’re very excited to support our local students to achieve their career goals and provide the best care to our patients in the community. With experienced pharmacist mentors, we can make a difference one patient, one legislator, one community at a time.
We’re in need of more pharmacists to join this initiative!
Be the positive influence on our future pharmacists and empower and educate them for the future of pharmacy. There is strength in numbers, and together we advance.

Click here to register

#togetherweadvance #theresstrengthinnumbers

DAPA & AbbVie Would Like to Invite You to the Women’s Health Sessions

Scroll down to choose your session!

Wednesday, June 23 at 6 PM CST.
Endometriosis and Elagolix, indicated for moderate to severe endometriosis pain.

One of the most common gynecologic disorders in the U.S., and affecting  roughly 10% (190 million) of reproductive age women and girls worldwide, endometriosis is a highly estrogen-dependent, chronic, inflammatory disease characterized by the growth of endometrial tissue (similar to the lining of the uterus) outside the uterus, causing pain and/or infertility. ORILISSA (Elagolix)represents the first FDA-approved gonadotropin releasing hormone receptor antagonist in the market, and oral treatment for the management of moderate to severe pain associated with endometriosis in over a decade.

This presentation will provide a brief overview of endometriosis disease state, and clinical trial data for Elagolix, indicated for moderate to severe endometriosis pain (FDA approved July 2018).


Thursday, June 24 at 6 PM CST.
UTERINE FIBROIDS & Elagolix+Estradiol/NETA, indicated for heavy menstrual bleeding associated with uterine leiomyomas in pre-menopausal women

Uterine fibroids, also called leiomyomas, are estrogen and progesterone-dependent non-cancerous tumors of the uterus and are the most common type of benign tumor in women of reproductive age. Traditionally, uterine fibroids have been primarily managed by surgery and are the leading reason for the hysterectomies performed in the U.S. ORIAHNN (Elagolix+Estradiol/NETA) is the first FDA-approved non-surgical, oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women.

This presentation will provide a brief scientific overview of disease state and clinical trial data for Elagolix+E2/NETA, indicated for heavy menstrual bleeding associated with fibroids (FDA approved May 2020).